alexa Management of Infliximab Treated Patients with Psoriasi
ISSN: 2155-9554

Journal of Clinical & Experimental Dermatology Research
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Management of Infliximab Treated Patients with Psoriasis Based On Infliximab Plasma Levels and Antibodies to Infliximab

Peter Kozub1, Andrea Kovacikova Curkova1*, Maria Zuzulova2 and Maria Simaljakova1

1Comenius University Faculty of Medicine, Bratislava, Slovakia

2St. Elizabeth Cancer Institute, Bratislava, Slovakia

*Corresponding Author:
Andrea Kovacikova Curkova
Dermatovenerologist, Researcher
Department of Dermatology and Venerology
Comenius University Faculty of Medicine
Bratislava, Mickiewiczova 13 Bratislava, 81369, Slovakia
Tel: 421904477133
E-mail: [email protected]

Received date: February 03, 2014; Accepted date: March 17, 2014; Published date: March 24, 2014

Citation: Kozub P, Curkova AK, Zuzulova M, Simaljakova M (2014) Management of Infliximab Treated Patients with Psoriasis Based On Infliximab Plasma Levels and Antibodies to Infliximab. J Clin Exp Dermatol Res 5: 214. doi: 10.4172/2155-9554.1000214

Copyright: © 2014 Kozub P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Background: Infliximab is the fastest acting biological agent in psoriasis treatment due to the possibility of intravenous administration and a well-conducted induction phase of treatment (week 0, 2, and 6). Another advantage is the weight-based dosing. However, disadvantages include the risk of infusion reactions and the production of neutralizing antibodies that are responsible for the secondary loss of efficacy.

Objectives: To analyze the dynamics of infliximab levels during one maintenance interval as well as the levels of anti-infliximab antibodies in patients with psoriasis treated with infliximab for a period of at least 22 weeks.

Methods: We followed 25 patients with psoriasis treated with infliximab for a period of at least 22 weeks at a dose of 5 mg/kg. Based on the clinical picture at the time of blood sample collection, the patients were divided into responders, partial responders and non-responders. Plasma levels of infliximab and antibodies to infliximab were examined in venous blood samples taken during one maintenance interval. The levels of infliximab were examined in week 0, 2, 4, 6, 7 and 8 and anti-infliximab antibodies were examined in week 8.

Results: According to the obtained data of infliximab levels and anti-infliximab antibodies, we divided the patients into 4 groups-responders, responders with shortened period of efficacy, non-responders with production of antibodies, and non-responders without production of antibodies. The dynamics of infliximab levels and the production of antiinfliximab antibodies were characteristic for each group. A definitive therapeutic management was created specifically for each group of patients.

Conclusions: Monitoring the dynamics of infliximab levels and anti-infliximab antibodies is not only of scientific importance, but it may be crucial in daily clinical practice, enabling an objective management of infliximab treatment.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords